Advanced thymic epithelial tumour resection: vascular resection and reconstruction strategy.

IF 1.9 3区 医学 Q3 RESPIRATORY SYSTEM Journal of thoracic disease Pub Date : 2025-01-24 Epub Date: 2025-01-22 DOI:10.21037/jtd-24-1395
Akshay J Patel, Eleni Josephides, Rajdeep Bilkhu, Paolo Bosco, Gianluca Lucchese, Andrea Bille
{"title":"Advanced thymic epithelial tumour resection: vascular resection and reconstruction strategy.","authors":"Akshay J Patel, Eleni Josephides, Rajdeep Bilkhu, Paolo Bosco, Gianluca Lucchese, Andrea Bille","doi":"10.21037/jtd-24-1395","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thymic epithelial tumors (TETs) represent the predominant primary malignancy of the anterior mediastinum, often necessitating complex surgical interventions due to their invasive nature. The prognosis of advanced TET relies significantly on achieving complete resection with microscopically clear margins (R0). This frequently entails resection and reconstruction of major vascular structures like the superior vena cava (SVC) and brachiocephalic veins, and in some cases, extra pleural pneumonectomy (EPP). The aim of the study is to interrogate our series of advanced TET resections.</p><p><strong>Methods: </strong>We analysed our experience with vascular resection and reconstruction in 14 patients with advanced stage III/IV TET undergoing extensive resection post-neoadjuvant chemotherapy. A comprehensive preoperative evaluation was performed, including computed tomography (CT), positron emission tomography (PET), biopsy, and exercise testing. We describe our surgical approach and the details of our series.</p><p><strong>Results: </strong>From 2015 to 2023, 31 patients underwent surgery for advanced TET at our centre, with major vessel reconstruction performed in 14 cases. This included resection of SVC and innominate veins with subsequent reconstruction using polytetrafluoroethylene (PTFE) grafts. The median operative time was 350 minutes, with a median blood loss of 1,300 mL. Cardiopulmonary bypass (CPB) was required in 2 cases. The rate of R0 resection was 78.6%, with a recurrence rate of 14.3% at a median follow-up of 1,700 days. Postoperative complications occurred in 42.9% of patients, with an in-hospital mortality rate of 7.1%.</p><p><strong>Conclusions: </strong>Multi-disciplinary management, meticulous preoperative planning, and advanced surgical techniques are essential for the successful treatment of advanced TET. Complex vascular resections should be reserved for high-volume centres to optimize outcomes.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 1","pages":"299-307"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833585/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of thoracic disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/jtd-24-1395","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Thymic epithelial tumors (TETs) represent the predominant primary malignancy of the anterior mediastinum, often necessitating complex surgical interventions due to their invasive nature. The prognosis of advanced TET relies significantly on achieving complete resection with microscopically clear margins (R0). This frequently entails resection and reconstruction of major vascular structures like the superior vena cava (SVC) and brachiocephalic veins, and in some cases, extra pleural pneumonectomy (EPP). The aim of the study is to interrogate our series of advanced TET resections.

Methods: We analysed our experience with vascular resection and reconstruction in 14 patients with advanced stage III/IV TET undergoing extensive resection post-neoadjuvant chemotherapy. A comprehensive preoperative evaluation was performed, including computed tomography (CT), positron emission tomography (PET), biopsy, and exercise testing. We describe our surgical approach and the details of our series.

Results: From 2015 to 2023, 31 patients underwent surgery for advanced TET at our centre, with major vessel reconstruction performed in 14 cases. This included resection of SVC and innominate veins with subsequent reconstruction using polytetrafluoroethylene (PTFE) grafts. The median operative time was 350 minutes, with a median blood loss of 1,300 mL. Cardiopulmonary bypass (CPB) was required in 2 cases. The rate of R0 resection was 78.6%, with a recurrence rate of 14.3% at a median follow-up of 1,700 days. Postoperative complications occurred in 42.9% of patients, with an in-hospital mortality rate of 7.1%.

Conclusions: Multi-disciplinary management, meticulous preoperative planning, and advanced surgical techniques are essential for the successful treatment of advanced TET. Complex vascular resections should be reserved for high-volume centres to optimize outcomes.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
晚期胸腺上皮肿瘤切除术:血管切除和重建策略。
背景:胸腺上皮肿瘤(TETs)是前纵隔主要的原发性恶性肿瘤,由于其侵袭性,通常需要复杂的手术干预。晚期TET的预后很大程度上依赖于显微镜下边缘清晰的完全切除(R0)。这通常需要切除和重建主要血管结构,如上腔静脉(SVC)和头臂静脉,在某些情况下,需要胸膜外全肺切除术(EPP)。本研究的目的是探讨我们的一系列先进TET切除术。方法:我们分析了14例晚期III/IV期TET患者在新辅助化疗后进行广泛切除术的血管切除和重建的经验。术前进行全面评估,包括计算机断层扫描(CT)、正电子发射断层扫描(PET)、活检和运动测试。我们描述我们的手术方法和我们系列的细节。结果:2015年至2023年,31例患者在我中心接受了晚期TET手术,其中14例进行了大血管重建。这包括切除SVC和无名静脉,随后用聚四氟乙烯(PTFE)移植物重建。中位手术时间350分钟,中位失血量1300 mL。2例需要体外循环(CPB)。R0切除率为78.6%,中位随访1700天复发率为14.3%。术后并发症发生率为42.9%,住院死亡率为7.1%。结论:多学科管理、周密的术前计划和先进的手术技术是晚期TET成功治疗的关键。复杂血管切除应保留在大容量中心,以优化结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of thoracic disease
Journal of thoracic disease RESPIRATORY SYSTEM-
CiteScore
4.60
自引率
4.00%
发文量
254
期刊介绍: The Journal of Thoracic Disease (JTD, J Thorac Dis, pISSN: 2072-1439; eISSN: 2077-6624) was founded in Dec 2009, and indexed in PubMed in Dec 2011 and Science Citation Index SCI in Feb 2013. It is published quarterly (Dec 2009- Dec 2011), bimonthly (Jan 2012 - Dec 2013), monthly (Jan. 2014-) and openly distributed worldwide. JTD received its impact factor of 2.365 for the year 2016. JTD publishes manuscripts that describe new findings and provide current, practical information on the diagnosis and treatment of conditions related to thoracic disease. All the submission and reviewing are conducted electronically so that rapid review is assured.
期刊最新文献
First-line treatment strategies for BRAF-V600E mutated non-small cell lung cancer: lessons from real-world data and ongoing uncertainties. Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study. Hemoglobin glycation index and mortality risk in severe community-acquired pneumonia: a retrospective study. Liposomal bupivacaine for postoperative analgesia after thoracoscopic surgery: a systematic review and meta-analysis. Isoforskolin inhibits LUBAC/GSDMD/IL-1β cascades in pulmonary fibrosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1